EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia

Naval G Daver iD, Amer M Zeidan iD, Anthony S Stein, Joshua F Zeidner, Keri Maher, Emily Curran, Dale Bixby, Wanxing Chai-Ho, Maximilian Stahl, Karen W L Yee, Don Stevens, Sawa Ito und 13 weitere

Cancer · 01.10.2026 · 132 (19)

DOI: 10.1002/cncr.70626 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer, online erschienen am 04.10.2026. Verfasst von Naval G Daver und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, CD47 Antigen, CD40 Antigens. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This clinical trial sought to determine whether SL‐172154 could be combined safely and improve the efficacy of azacitidine (AZA) in patients with higher‐risk myelodysplastic syndrome (HR‐MDS) or acute myeloid leukemia (AML).

Methods

Dose escalation: doses of 1, 3, and 6 mg/kg SL‐172154 was evaluated as monotherapy or in combination with AZA in patients with relapsed, refractory HR‐MDS or AML. Expansion: a SL‐172154 dose that could be safely combined with AZA was evaluated in patients with previously untreated HR‐MDS or TP53 mutant ( TP53 m) AML. Objectives: safety, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity.

Results

Eighty‐one patients with HR‐MDS ( n = 33) or AML ( n = 48) were enrolled in dose escalation ( n = 37) or expansion ( n = 44). Infusion‐related reaction was the most common SL‐172154‐related toxicity and led to a dose limiting toxicity at 6 mg/kg. A dose of 3 mg/kg SL‐172154 plus AZA was evaluated in patients with previously untreated HR‐MDS ( n = 21 with TP53 m and n = 3 with TP53 wild type) and AML ( n = 21 with TP53 m). CD47 and CD40 engagement by SL‐172154 was detected on leukemic blasts, myeloid, and lymphoid cells. Complete remission (CR) was achieved in 10 of 24 (43%) HR‐MDS and six of 21 (29%) TP53 m AML patients with median overall survival (OS) of 11.0 months (95% CI, 5.0–15.6) and 11.7 months (95% CI, 1.97–NE), respectively. Of patients in a CR, six of 10 HR‐MDS and three of six TP53 m AML patients achieved complete cytogenetic CR.

Conclusions

SL‐172154 plus AZA was generally well tolerated with favorable CR rates in pts with TP53 m HR‐MDS or AML, although without substantial improvement in OS when compared to historical benchmarks for AZA or AZA/VEN, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteCD47 AntigenCD40 AntigensRecombinant Fusion ProteinsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleAgedMaleMiddle AgedAzacitidineAdultAged, 80 and overCD40 LigandDose-Response Relationship, Drug

Stichwörter der Autor:innen

CD40CD47acuteimmunotherapyleukemiamyelodysplastic syndromesmyeloid

Substanzen

CD47 AntigenAzacitidineCD40 AntigensCD47 protein, humanRecombinant Fusion ProteinsCD40 Ligand

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Internal Medicine, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, Connecticut, USA.
  • City of Hope Cancer Center, Duarte, California, USA.
  • University of North Carolina, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
  • VCU Massey Cancer Center, Richmond, Virginia, USA.
  • University of Cincinnati, Cincinnati, Ohio, USA.

ORCID-Profile: Naval G Daver, Amer M Zeidan, Emma Searle, Lini Pandite, David A Sallman

Zitieren

APA

Daver, N. G., Zeidan, A. M., Stein, A. S., Zeidner, J. F., Maher, K., Curran, E., Bixby, D., Chai-Ho, W., Stahl, M., Yee, K. W. L., Stevens, D., Ito, S., Reynolds, J., Medd, P., Searle, E., Sochacki, A., Savoie, M. L., Green, S., Kato, K., …, & Sallman, D. A. (2026). Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia. Cancer, 132(19). https://doi.org/10.1002/cncr.70626

Vancouver

Daver NG, Zeidan AM, Stein AS, Zeidner JF, Maher K, Curran E, et al. Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia. Cancer. 2026;132(19). doi:10.1002/cncr.70626

BibTeX
@article{Daver2026,
  author = {Daver, Naval G and Zeidan, Amer M and Stein, Anthony S and Zeidner, Joshua F and Maher, Keri and Curran, Emily and Bixby, Dale and Chai-Ho, Wanxing and Stahl, Maximilian and Yee, Karen W L and Stevens, Don and Ito, Sawa and Reynolds, Jana and Medd, Patrick and Searle, Emma and Sochacki, Andrew and Savoie, Mary Lynn and Green, Steven and Kato, Kazunobu and Hernandez, Robert and Metenou, Simon and Ma, Bo and Pandite, Lini and Schreiber, Taylor H and Sallman, David A},
  title = {Phase 1 dose escalation and expansion trial of the bispecific CD47 inhibitor and CD40 agonist Fc‐fusion protein SL‐172154 (SIRPα‐Fc‐CD40L) in patients with higher‐risk myelodysplastic syndrome or acute myeloid leukemia},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {19},
  doi = {10.1002/cncr.70626}
}
Kostenlos starten →